About this trial
Schizoaffective disorder (SAD) is a chronic psychiatric condition characterized by psychotic and mood symptoms. Emerging evidence suggests that Leucine-Rich Repeat and Fibronectin Type-III Domain-Containing Protein 5 (LRFN5) and olfactomedin-4 (OLFM4) may play roles in synaptic organization, neurodevelopment, and neuroinflammation. However, no prior study has investigated these biomarkers in SAD. This cross-sectional case-control study aims to compare peripheral serum levels of LRFN5 and OLFM4 in subjects diagnosed with SAD in remission and healthy control subjects. The study also assessed associations between these biomarkers and clinical symptom severity, global functioning, and systemic inflammation measured by the Aggregate Index of Systemic Inflammation (AISI). The study aimed to investigate convergent synaptic and immunoinflammatory dysregulation in SAD.
Eligibility criteria
Qualifiers
Diagnosis of SAD according to DSM-5-TR
Acute manic episode
Medication-free for at least one month prior to admission
Age ≥ 18 years and <65 years
Disqualifiers
Alcohol/drug/substance use
Medication-free for at least one month
Age ≥ 18 years and < 65 years
Provided informed consent
Trial design
Treatments tested in this trial
- Not listed